Article
Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
Expert opinion on drug metabolism & toxicology - 1 Jan 2018
Hamilton Gerhard, Rath Barbara
Abstract excerpt
INTRODUCTION: The efficacy of platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC) is limited by chemoresistance. Platinum drugs damage DNA by introducing intrastrand and interstrand crosslinks which result in cell death. Excision repair cross-complementing 1 (ERCC1) is a member of the nucleotide excision repair (NER) pathway which erases such defects. Single nucleotide polymorphisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
